The NIFTY opened at 16870.55 with a big gap down of 137 points. Initially, the index moved lower but quickly turned around and started rising after recording a low of around 16825. The index has seen a sharp intraday rally of about 200 points, filled the gap, and moved above 17000. However, the index found strong resistance there and started drifting downwards. Prices have recorded its intraday high at 17037.60, moved down below the early morning low, and recorded its intraday low at 16820.40. The index finally closed at 16858.60 with a loss of 148.80 points or 0.87% down. PHARMA outperformed today by ending 0.85% up followed by IT which ended up by 0.24%. BANK and FINANCIAL underperformed today leading the bears and ending lower by 1.56% & 1.23% respectively. The short-term trend is down. We have mentioned a strong support zone around 16800 – 17000. We have news even this week as the RBI will announce the policy meeting’s outcome on Friday. It will increase the volatility which is already very high as the INDIA VIX, a benchmark index for volatility is now moving around 22. A move below 20 will be the first sign of a stable market. We should now wait for prices to find support and form a consolidation. Till then avoid trading the index.


The BANK NIFTY opened at 38081.25 with a big gap down of 439 points. The index initially moved down but quickly rebound and turned up. A rally started but failed to fill the gap and prices turned down after recording its intraday high at 38368.80. The index has seen a sharp decline till the end, recorded its intraday low at 37626.20, and finally dosed at 37663.50 near its day lows with a loss of 857 points. PVT and PSU BANKS both indices have performed almost the same today, saw a sharp decline, and closed lower by 1.44% & 2.07% respectively. Within the index, in terms of points, HDFC BANK contributed the highest on the downside followed by AXIS BANK. The decline continued for the sixth consecutive trading day and the index dosed lower with a loss of over one and a half percent. Prices moved very volatile after a gap down opening and saw a sharp intraday fall in the second half. The short-term trend is down which is obvious. Support around 38000 broken down and next support may emerge around 37000. Resistance is visible at around 39500. We should wait for this decline to be stopped and then form some kind of consolidation.


TCS 3035.65 BUY The stock has given the breakout on the intraday as well as the daily chart. The stock can be bought at 3041 with a stop loss of 3076 and for the target of 3018.
DIXON 4290 BUY The stock has given the breakout on the intraday as well as the daily chart. The stock can be bought at CMP with a stop loss of 4215 and for the target of 4414.


Stock Name Strike Price Buy/Sell CMP Initiation Stop Loss Target Remarks
DIVIS LAB (27 OCT) 3800 (CE) BUY 90 CMP 70 127 BREAK OUT
Long Buildup Short Buildup
Stocks Price Price% OI % OI Stocks Price Price% OI % OI
MUTHOOTFIN.2209Sep 1047.5 3.66 4.86 2490375 MOTHERSON.22.09 Sep 106.3 -5.05 17.12 30541500
ASIANPAINT.22.09 Sep 3569.8 2.88 30.6 3595200 AUBANK.22.09 Sep 581.25 -4.21 0.57 2666000
RAMCOCEM.22.09 Sep 737.9 2.86 3.09 1133900 HINDALCO.22.09 Sep 359 -4.11 11.51 17137650
LUPIN.22.09 Sep 669.95 1.89 10.13 3972900 BANDHANBNK.22.09 Sep 253.05 -3.89 7.8 13509000
MARICO.22.09 Sep 545.7 1.8 15.38 3078000 JSWSTEEL.22.09 Sep 615.6 -3.5 8.12 8699400
                                                                        Short Covering                                                                       Long Unwinding
INDIACEM.22.09 Sep 248.15 7.22 -6.47 4779200 PNB.22.09 Sep 34.8 -5.31 -2.55 163696000
ABFRL.22.09 Sep 328.1 2.39 -2.88 3156400 CHAMBLFERT.22.09 Sep 301.75 -5.18 -2.61 3300000
METROPOLIS.22.09 Sep 1519.45 2.3 -20.81 293400 DELTACORP.22.09 Sep 191.45 -4.54 -16.27 6428500
UBL.22.09 Sep 1689.5 2.01 -6.98 602800 HINDCOPPER.22.09 Sep 100.45 -3.88 -5.38 11485300
ZYDUSLIFE.22.09 Sep 367.5 1.97 -0.91 5907600 M&MFIN.22.09 Sep 176.2 -3.74 -8.39 10396000


Stocks Price %Chg Total Qty Delivery Del % % Change
Sectors Price Change % Quantity
Rec Limited 95.65 -1.24 6792547 0 75.66 Nifty50 16858.6 -0.87 73311
Abbott India Limited 18140.2 0.33 28542 0 71.59 Niftybank 37759.85 -1.56 73311
Godrej Cons Products Ltd 885.05 0.2 923453 0 70.43 Nifty it 27067.65 0.24 73311
Hdfc Ltd. 2244.05 -1.97 2807467 0 68.36 India Vix 22.1 2.46 73311
Bharti Airtel Limited 761.45 0.11 5544699 0 68.09 Nifty Fmcg 43964.65 -0.57 73311
City Union Bank Ltd. 171.25 -0.15 3192281 0 66.82 Nifty Pharma 12705.4 0.85 73311
Icici Bank Ltd. 849.5 -0.36 11411213 0 66.58 Nifty Realty 414.25 -0.67 73311
Infosys Limited 1394.7 0.08 7021716 0 66.55 Nifty Auto 12537.35 0.06 73311
Dabur India Ltd. 564.05 0.63 1551458 0 65.72 Nifty Metal 5617.65 -1.94 73311
Axis Bank Limited 716.45 -2.85 13151345 0 65.33 Nifty Financial Services 17210.05 -1.23 73311


   Domestic                                                                                                                                                  International
INR: Interest Rate Decision on 30th September, 2022

INR: RBI MPC Meeting Minutes on 30th September, 2022

 USD: GDP (QoQ) (Q2) on 29th September, 2022

USD: Initial Jobless Claims on 29th September, 2022


  • Benchmark indices ended on negative note with Nifty below 16900 in the volatile session on September 28. At Close, the Sensex was down 509.24 points or 0.89% at 56,598.28, and the Nifty was down 148.80 points or 0.87% at 16,858.60. About 1296 shares have advanced, 2039 shares declined, and 103 shares are unchanged.
  • Reliance Industries Ltd., Infosys Ltd. and Tata Consultancy Services Ltd. are set to see their weight decline in the Nifty 50 index following Adani Enterprises Ltd.’s entry, according to Edelweiss Securities Ltd. Adani Enterprises’ inclusion with a weight of 1.29% from Sept. 30 will attract inflows of Rs 33.60 crore, Edelweiss said in its report.
  • Shares of Torrent Pharmaceuticals Ltd. fell the most in eight months after analysts said the valuation of its acquisition of Curatio Healthcare (I) Pvt. is expensive even as they expect the deal to enhance the drugmaker’s presence in dermatology and inch up its revenue from the segment. Torrent Pharma has agreed to fully acquire the sunscreen lotions-to-baby-soap maker for a cash consideration of Rs 2,000 crore, according to its Sept. 27 exchange filing.
  • The Indian rupee closed at a record low against the U.S. dollar on Wednesday. The local currency fell 0.37% to 81.87 at open. During the day, the rupee depreciated as much as 0.46% to its intraday low of 81.95—a fresh record low. It ended Wednesday’s trade at 81.94, its worst close ever.
Source: Economic Times,  Indian Express, Business Today, Livemint, Business Standard, Bloomberg Quint


Company Name Purpose Meeting Date Company Name Purpose Meeting Date
ANJANIFOODS Stock  Split 29-Sep-22 MANGIND General 06-Oct-22
BSELINFRA General 29-Sep-22 CRSTCHM General 07-Oct-22
GGL Rights Issue 29-Sep-22 NETTLINX General 07-Oct-22
GOACARBON Right Issue of Equity Shares;General 29-Sep-22 WARDINMOBI Right Issue of Equity Shares;General;Rights Issue 07-Oct-22
INDINFR General 29-Sep-22 GLCL Audited Results;Quarterly Results 10-Oct-22
JAINCO General 29-Sep-22 MEFCOMCAP Stock  Split 10-Oct-22
KAARYAFSL General 29-Sep-22 SUPREMEINF Quarterly Results 11-Oct-22
MPL General 29-Sep-22 INFY Audited Results;Interim Dividend;Quarterly Results 13-Oct-22
SAPPL Right Issue of Equity Shares;Rights Issue 29-Sep-22 BAJAJ-AUTO* Quarterly Results 14-Oct-22
HERITGFOOD Right Issue of Equity Shares;General 30-Sep-22 SHREECEM Quarterly Results 14-Oct-22
INTETHR A.G.M. 30-Sep-22 SYSCO General 14-Oct-22
MACKINN Quarterly Results 30-Sep-22 HDFCBANK Quarterly Results 15-Oct-22
MDRNSTL Quarterly Results 30-Sep-22 ICICIGI Audited Results;Interim Dividend 18-Oct-22
MSUMI Bonus issue 30-Sep-22 JCHAC Quarterly Results 19-Oct-22
NAYSAA A.G.M. 30-Sep-22 MAHSCOOTER Quarterly Results 19-Oct-22
SAGARSOFT Quarterly Results 30-Sep-22 NESTLEIND Quarterly Results 19-Oct-22
SCANPRO A.G.M. 30-Sep-22 PERSISTENT General;Quarterly Results 19-Oct-22
FEDDERELEC General;Quarterly Results 01-Oct-22 BAJFINANCE Quarterly Results 20-Oct-22
GOYALASS General 01-Oct-22 LAXMIMACH Quarterly Results 20-Oct-22
TTFL General 01-Oct-22 UTIAMC Quarterly Results 20-Oct-22
DHANADACO General 03-Oct-22 BAJAJFINSV Quarterly Results 21-Oct-22
GETALONG General 03-Oct-22 BAJAJHLDNG Quarterly Results 21-Oct-22
HDIL Audited Results;Quarterly Results 03-Oct-22 RKFORGE Interim Dividend;General;Quarterly Results 21-Oct-22
ROJL General 03-Oct-22 ICICIBANK Quarterly Results 22-Oct-22
SARDAPPR General;Preferential Issue of shares 03-Oct-22 IDFCFIRSTB Quarterly Results 22-Oct-22
PULSRIN Increase in Authorised Capital;General 04-Oct-22 DABUR Interim Dividend;Quarterly Results 26-Oct-22
PUNITCO Bonus issue;Increase in Authorised Capital 04-Oct-22 TTKPRESTIG Quarterly Results 04-Nov-22
YUG General 04-Oct-22 ENDURANCE Quarterly Results 07-Nov-22


Company Name Ex-Date Purpose Company Name Ex-Date Purpose
ALFAVIO 29-Sep-22 Dividend – Rs. – 0.0500 AHLEAST 06-Oct-22 Spin Off
THAMBBI 29-Sep-22 E.G.M. INDINFR 06-Oct-22 Income Distribution (InvIT)
INSECTICID 30-Sep-22 Bonus issue 1:2 SPAL 06-Oct-22 Buy Back of Shares
MAXIMUS 30-Sep-22 Stock  Split From Rs.10/- to Rs.1/- ANSHNCO 07-Oct-22 Bonus issue 4:1
JONJUA 03-Oct-22 Bonus issue 4:23 RUCHIRA 07-Oct-22 Bonus issue 1:10
MOTHERSON 03-Oct-22 Bonus issue 1:2 UNICK 10-Oct-22 E.G.M.
YUG 03-Oct-22 Bonus issue 1:2 KAARYAFSL 12-Oct-22 Bonus issue 1:1
LEHAR 04-Oct-22 E.G.M. JAICORPLTD 20-Oct-22 Dividend – Rs. – 0.5000
MLINDLTD 04-Oct-22 Bonus issue 6:1 VGIL 20-Oct-22 Final Dividend – Rs. – 0.2000
MLINDLTD 04-Oct-22 Final Dividend – Rs. – 0.5000 ICICIGI 27-Oct-22 Interim Dividend
ACCELYA 06-Oct-22 Final Dividend – Rs. – 45.0000 PGHH 04-Nov-22 Final Dividend – Rs. – 65.0000
AHLEAST 06-Oct-22 Bonus issue 1:2 GILLETTE 10-Nov-22 Final Dividend – Rs. – 36.0000


Disclosure in pursuance of Section 19 of SEBI (RA) Regulation 2014

Elite Wealth Limited does/does not do business with companies covered in its research reports. Investors should be aware that the Elite Wealth Limited may/may not have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only information in making their investment decision and must exercise their own judgment before making any investment decision.
For analyst certification and other important disclosures, see the Disclosure Appendix, or go to Analysts employed by Elite Wealth Limited are registered/qualified as research analysts with SEBI in India.( SEBI Registration No.: INH100002300)
Disclosure Appendix
Analyst Certification (For Reports)
Israil Khan, Elite Wealth Limited,
The analyst(s) certify that all of the views expressed in this report accurately reflect my/our personal views about the subject company or companies and its or their securities. I/We also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Elite Wealth Limited.
As to each individual report referenced herein, the primary research analyst(s) named within the report individually certify, with respect to each security or issuer that the analyst covered in the report, that:
(1) all of the views expressed in the report accurately reflect his or her personal views about any and all of the subject securities or issuers; and
(2) no part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in the report.
For individual analyst certifications, please refer to the disclosure section at the end of the attached individual notes.
Research Excerpts
This note may include excerpts from previously published research. For access to the full reports, including analyst certification and important disclosures, investment thesis, valuation methodology, and risks to rating and price targets, please visit
Company-Specific Disclosures
Important disclosures, including price charts, are available and all Elite Wealth Limited covered companies by visiting, or emailing with your request. Elite Wealth Limited may screen companies based on Strategy, Technical, and Quantitative Research. For important disclosures for these companies, please e-mail
Options related research:
If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk disclosure documents. For a copy of the risk disclosure documents, please contact your Broker’s Representative or visit the OCC’s website at
Other Disclosures
All research reports made available to clients are simultaneously available on our client websites. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research reports available on a particular stock, please contact your respective broker’s sales person.
Ownership and material conflicts of interest Disclosure
Elite Wealth Limited policy prohibits its analysts, professionals reporting to analysts from owning securities of any company in the analyst’s area of coverage. Analyst compensation: Analysts are salary based permanent employees of Elite Wealth Limited. Analyst as officer or director: Elite Wealth Limited policy prohibits its analysts, persons reporting to analysts from serving as an officer, director, board member or employee of any company in the analyst’s area of coverage.
Country Specific Disclosures
India – For private circulation only, not for sale.
Legal Entities Disclosures
Mr. Ravinder Parkash Seth is the Managing Director of Elite Wealth Ltd (EWL, henceforth), having its registered office at Casa Picasso, Golf Course Extension, Near Rajesh Pilot Chowk, Radha Swami, Sector-61, Gurgaon-122001 Haryana, is a SEBI registered Research Analyst and is regulated by Securities and Exchange Board of India. Telephone:011-43035555, Facsimile: 011-22795783 and Website:
EWL discloses all material information about itself including its business activity, disciplinary history, the terms and conditions on which it offers research report, details of associates and such other information as is necessary to take an investment decision, including the following:
1. Reports
a) EWL or his associate or his relative has no financial interest in the subject company and the nature of such financial interest;
(b) EWL or its associates or relatives, have no actual/beneficial ownership of one per cent. or more in the securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;
(c) EWL or its associate or his relative, has no other material conflict of interest at the time of publication of the research report or at the time of public appearance;
2. Compensation
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) EWL or its associates have not managed or co-managed public offering of securities for the subject company in the past twelve months;
(c) EWL or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(d) EWL or its associates have not received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(e) EWL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report.
3 In respect of Public Appearances
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) The subject company is not now or never a client during twelve months preceding the date of distribution of the research report and the types of services provided by EWL